Poseida Therapeutics(PSTX) - 2023 Q4 - Annual Report
Poseida Therapeutics(PSTX)2024-03-08 05:24
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39376 POSEIDA THERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 47-2846548 (State ...